Gri bio raises a total of $13.9 million in gross proceeds since the beginning of 2024

Proceeds from recent exercise of warrants estimated to extend cash runway into mid q1 2025, including interim data readout from phase 2a biomarker study of lead program, gri-0621 for the treatment of idiopathic pulmonary fibrosis (ipf)
GRI Ratings Summary
GRI Quant Ranking